Portada Simposios - Supplements - Haematologica

XLII Reunión Nacional de la AEHH y XVI Congreso de la SETH. Programa educacional
53
56. Chan FK, Zhang J, Cheng L, Shapiro DN, Winoto A. Identification of
human and mouse p19, a novel CDK4 and CDK6 inhibitor with homology
to p16INK4. Mol Cell Biol 1995; 15: 2682-2688.
57. Hollstein M, Sidransky D, Vogelstein B, Harris CC. P53 mutation in
human cancers. Science 1991; 88: 8405-8410.
58. Imamura J, Miyoshi I, Koeffler HP. P53 in hematologic malignancies.
Blood 1994; 84: 2412-2421.
59. Fenaux P, Jonveaux P. P53 gene alterations in acute myeloid leukemia
with 17p monosomy. Blood 1991; 78: 1652-1657.
60. Sugimoto K, Hirano N, Toyoshima H, Chiba S, Mano H, Takaku F et
al. Mutations of the p53 gene in myelodysplastic syndrome (MDS)
and MDS-derived leukemia. Blood 1993; 81: 3022-3330.
61. Wada M, Bartram CR, Nakamura H, Hachiya M, Chen DL, Borenstein
J et al. Analysis of p53 mutations in large series of lymphoid hematological
malignancies of childhood. Blood 1993; 82: 3163-3169.
62. Fenaux P, Jonveaux P. Mutations of p53 gene in B-cell lymphoblastic
acute leukemia. Leukemia 1992; 6: 42-46.
63. Dicciani MB. Clinical significance of p53 mutations in relapsed T-cell
acute lymphoblastic leukemia. Blood 1994; 84: 3105-3112.
64. Michael H. Non hereditary p53 mutations in T-cell acute lymphoblastic
leukemia are associated with the relapsed phase. Blood 1994; 83:
2922-2930.
65. Chilosi M, Doglioni C, Magalini A, Inghirami G, Krampera M, Nadali
G et al. P21/Waf1 cyclin-kinase inhibitor expression in non-Hodgkin’s
lymphomas; a potential marker of p53 tumor-suppressor gene function.
Blood 1996; 88: 4012-4020.
66. Villuendas R, Pezzella F, Gatter K, Algara P, Sánchez Beato M, Martínez
P et al. P21/Waf1/CIP1 and Mdm2 expression in non-Hodgkin’s
lymphoma and their relationship top53 status: a p53 + , Mdm2-,
p21-immunophenotype associated with missense p53 mutations.
J Pathol 1997; 181: 51-61.
67. Lo Coco F, Gaidano G, Louie DC, Offit K, Chaganti RSK, Dalla-Favera
R. P53 mutations are associated with histologic transformation of follicular
lymphoma. Blood 1993; 82: 2289-2295.
68. Sander CA, Yano T, Clark HM, Harris C, Longo DL, Jaffè Es et al. P53
mutation is associated with progression in follicular lymphomas. Blood
1993; 82: 1994-2000.
69. Villuendas R, Piris MA, Orradre JL, Mollejo M, Algara P, Sánchez L et
al. P53 protein expression in lymphomas and reactive lymphoid tissue.
J Pathol 1992; 166: 235-242.
70. Ner A, Baldini L, Trecca D, Cro L, Polli E, Maiolo AT. P53 mutations in
multiple myeloma are associated with advanced forms of malignancy.
Blood 1993; 81: 128-134.
71. Preudhomme C, Facon T, Zandecki M, Vantumbeke M, Lai JL, Nataf E
et al. Rare occurrence of p53 gene mutations in multiple myeloma. Br
J Haematol 1992; 81: 440-448.
72. Weinberg RA. Tumor suppressor genes. Science 1991; 254: 1138-
1146.
73. Jares P, Campo E, Pinyol M, Bosch F. expression of retinoblastoma
gene product (pRb) in mantle cell lymphomas. Correlation with Cyclin
D1(PRAD1/CCND1) mRNA levels and proliferative activity. Am J Pathol
1996; 148: 1591-1600.
74. Serrano M, Lee HW, Chin L, Cordon Cardo C, Beach D, Depinho R.
Role of the INK4a locus in tumor suppression and cell mortality. Cell
1996; 85: 27-37.
75. Drexler HG. Review of alterations of the cyclin-dependent kinase inhibitor
INK4 family genes p15, p16 p18 and p19 in human
leukemia-lymphoma cell. Leukemia 1998; 12: 845-859.
76. Yang R, Gombart AF, Serrano M, Koeffler HP. Mutational effects on
the p16/INK4a tumor suppressor protein. Cancer Res 1995; 55:
2503-2506.
77. Duro D, Bernard O, Valle VD. Leblanc T, Berger R, Larsen CJ. Inactivation
of the p16 INK4 /MTS1gene by a chromosome translocation
T(9;14) (p21-22;q11) in an acute lymphoblastic leukemia of B-cell
type. Cancer Res 1996; 56: 4848-4854.
78. Laï JL, Fenaux P, Pollet JP, Estienne MH, Savary JB, Huart JJ et al. Acute
lymphocytic leukemia with 9p anomalies. A report of four additional
cases and review of the literature. Cancer Genet Cytogenet 1998;
33: 99-109.
79. Atkin NB, Baker MC. Diffuse large cell (Kiel-1) lymphoma with a
t(9;11)(p21-22;q13) and a missing Y as the only chromosome changes.
Cancer Genet Cytogenet 1998; 101: 72-74.
80. García-Sanz R, González M, Vargas M, Chillón MC, Balanzategui A,
Barbón M et al. Deletions and rearrangements of cyclin-dependent
kinase 4 inhibitor gene p16 are associated with poor prognosis in B
cell non-Hodgkin’s lymphomas. Leukemia 1997; 11: 1915-1920.
81. Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, Carson DA. Deletions
of the cyclin-dependent kinase 4 inhibitor gene in multiple human
cancers. Nature 1994; 368: 753-756.
82. Kamb A, Gruis NA, Waver-Feldhaus J. A cell cycle regulator potentially
involved in the genesis of many tumor types. Science 1994; 264:
436-437.
83. Sidransky D. Two tracks but one race Cancer Genet Curr Biol 1996;
6: 523-526.
84. Singal R, Ginder G. DNA methylation. Blood 1999; 93: 4059-4070.
85. Sill H, Goldman JM, Cross NCP. Homozygous deletions of the p16
tumor-suppressor gene are associated with lymphoid transformation
of chronic myeloid leukemia. Blood 1995; 85: 2013-2016.
86. Dreyling MH, Bohlander SK, Le Beau MM, Olopade OI. Refined mapping
of genomic rearrangements involving the short arm of chromosome
9 in acute lymphoblastic leukemias and other hematologic malignancies.
Blood 1995; 86: 1931-1938.
87. Ogawa S, Hirano N, Sato N, Takahashi T, Hangaishi A, Tanalka K et
al. Homozygous loss of the cyclin-dependent kinase 4-inhibitor (p16)
gene in human leukemias. Blood 1994; 84: 2431-2435.
88. Quesnel B, Preudhomme C, Fenaux P. p16I NK4a gene and hematological
malignancies. Leuk Lymphoma 1996; 22: 11-24.
89. Duro D, Flexor M, Bernard O, d’Agay M, Berger R, Larsen C. Alterations
of the putative tumor suppressor gene p16/MTS1 in human hematologic
malignancies. Comptes Rend Acad Sci Paris 1994; 317:
913-919.
90. Hebert J, Cayuela JM, Berkeley J, Sigaux F. Candidate tumor-suppressor
genes MTS1 (p16INK4a) and MTS2 (p15INK4b) display frequent
homozygous deletions in primary cells from T-but not from B-cell lineage
acute lymphoblastic leukemias. Blood 1994; 84: 4038-4044.
91. Della Ragione F, Iolacson A. Inactivation of cyclin-dependent kinase
inhibitor genes and development of human acute leukemias. Leuk
Lymphoma 1997; 25: 23-35.
92. Cayuela JM, Hebert J, Sigaux F. Homozygous MTS1 (p16INK4a) deletion
in primary tumor cells of 63 leukemic patients. Blood 1995; 85:
854-861.
93. Otsuki T, Clark HM, Wellmann A, Jaffè ES, Raffeld M. Involvement of
CDKN2 (p16INK4a/MTS1) and p15INK4b/MTS2 in human leukemias
and lymphomas. Cancer Res 1995; 55: 1436-1440.
94. Ogawa S, Hangaishi A, Miyawaki s, Hirosawa S, Miura Y, Takeyama K
et al. Loss of the cyclin-dependent kinase 4-inhibitor (p16;MTS1) gene
is frequent in and highly specific to lymphoid tumors in primary human
hematopoietic malignancies. Blood 1995; 86: 1548-1556.
95. Stransk G, Height SE, Mitchell P, Jadayel D, Yuille MAR, de Lord C et
al. Deletions and rearrangements of CDKN2 in lymphoid malignancy.
Blood 1995; 85: 893-901.
96. Takeuchi S, Bartram CR, Seriu T, Miller CW, Tobler A, Janssen JWG
et al. Analysis of a family of cyclin-dependent kinase inhibitors:
p15/MTS2/INK4b, p16/MTS1/INK4a, and p18 genes in acute lymphoblastic
leukemia of childhood. Blood 1995; 86: 755-760.
97. Newcomb EW, Rao LLS, Giknavoian SS, Lee SY. Alterations of multiple
tumor suppressor genes (p53(17p13), p16INK4 (9p21), and DBM
(13q14) in B-cell chronic lymphocytic leukemia. Mol Carcinogenesis
1995; 14: 141-146.
98. Martel V, Guerci A, Humbert JC, Gregoire MT, Chery M, Lederlin P et
al. De novo methylation of tumour suppressor genes CDKN3A and
CDKN2B is a rare finding in B-cell chronic lymphocytic leukaemia. Br J
Haematol 1997; 99: 320-324.
99. Uchida T, Watanabe T, Kinoshita T, Murate T, Saito H, Hotta T. Mutational
analysis of the CDKN2 (MTS1/p16INK4a) gene in primary
B-cell lymphomas. Blood 1995; 86: 2724-2731.
100. Williams ME, Whitefield M, Swerdlow SH. Analysis of the cyclin-dependent
kinase inhibitors p18 and p19 in mantle-cell lymphoma and
chronic lymphocytic leukemia. Ann Oncol 1997; 8 (Supl): 71-73.
101. Chaganti SR, Gaidano G, Louie DC, Dalla-Favera R, Chaganti RSK.
Diffuse large cell lymphomas exhibit frequent deletions in 9p21-22
and 9q31-34 regions. Genes Chromosom Cancer 1995; 12: 32-36.
102. Koduru PRK, Zariwala M, Soni M, Gong JZ, Xiong Y, Broome JD. Deletion
of cyclin-dependent kinase 4 inhibitor genes p15 and p16 in
non-Hodgkin’s lymphoma. Blood 1995; 86: 2900-2905.
103. Fernández-Piqueras J, Santos J, Pérez de Castro I, Meléndez B, Martínez
B, Robledo M et al. Frequent allelic losses of 9p21 markers and low incidence
of mutations at p16(CDKN2) gene in non-Hodgkin lymphomas
of B-cell lineage. Cancer Genet Cytogenet 1997; 98: 63-68.
104. Fujiwara H, Arima N, Hidaka S, Ohtusubo H, Matrsuhita K, Kukita T
et al. Alteration of the CDKN2 (p16/INK4A/MTS1) gene in adult T cell
leukemia-lymphoma (ATLL). Blood 1995; 86: 563.ª
105. Hatta Y, Hirama T, Miller CW, Yamada Y, Tomonaga M, Koeffler HP.
Homozygous deletion of the p15 (MTS2) and p16 (MTS1) genes in
adult T-cell leukemia. Blood 1995; 85: 2699-2704.
106. Tasaka T, Berenson J, Vescio R, Hirama T, Miller CW, Nagai M et al.
Analysis of the p16INK4a, p15INK4b and p18INK4c genes in multiple
myeloma. Br J Haematol 1997; 96: 98-102.
107. Herman JG, Civin CI, Issa JPJ, Collector MI, Sharkis SJ, Baylin SB. Distinct
patterns of inactivation of p15INK4b and p16INK4a characterize
major types of hematological malignancies. Cancer Res 1997; 57:
837-841.
108. Iravani M, Dhat R, Price CM. Methylation of the multi tumor suppressor
gene-2 (MTS2, CDKN1, p15(INK4b) in childhood acute lymphoblastic
leukemia. Oncogene 1997; 15: 2609-2614.
109. Batova A, Diccianni MB, Nobori T, Vu T, Yu J, Bridgeman L et al. Frequent
deletion in the methyladenosine phosphorylase gene in T-cell
acute lymphoblastic leukemia: strategies for enzyme-targeted therapy.
Blood 1996; 88: 3083-3090.
110. Martínez-Delgado B, Fernández-Piqueras J, García MJ, Gallego J, Rivas
C, Robledo M, Benítez J. Hypermethylation of a 5’CpG island of p16 is
a frequent event in non-Hodgkin’s lymphoma. Leukemia 1997; 11:
425-428.
111. Gonzalez M, Mateos MV, García-Sanz R, Balanzategui A, López-Pérez
R, Chillón MC et al. De novo methylation of tumor suppressor gene
p16/INK4a is a frequent finding in multiple myeloma patients at diagnosis.
Leukemia 2000; 14: 183-187.
112. Mateos MV, García-Sanz R, López-Pérez R, Balanzategui A, González
MI, González D et al. P16/INK4a gene inactivation by hypermethylation
is associated with aggressive variants of monoclonal gammopathies.
Hematology J 2000 (in press).
113. Diccianni MB, Batova A, Yu J, vu T, Pullen J, Amylon M, Pollock BH, Yu
AL. Shortened survival after relapse in t-cell acute lymphoblastic leukemia
patients with p16/p15 deletions. Leukemia Res 1997; 21: 549-558.